GlassScriptPhysician profile
Carie M Brown
NPI 1750849758
$5,589.90
in general payments reported to CMS, 2019-2025
41 companies · $1,413 in 2025
The $1,413 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,198 · 2023: $1,539 · 2024: $1,440 · 2025: $1,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,392.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $803.03 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $596.08 | 2023-2025 | |
| Abbvie INC. | $562.20 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $521.96 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $449.44 | 2022-2025 | Caplyta |
| Astellas Pharma US INC | $330.79 | 2022-2025 | Veozah |
| Merck Sharp & Dohme LLC | $239.39 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Aimmune Therapeutics, INC. | $187.78 | 2024-2025 | Zenpep |
| Biohaven Pharmaceutical Holding Company LTD. | $157.47 | 2022 | |
| Amgen INC. | $155.97 | 2022-2025 | Repatha, Otezla, Prolia |
| Glaxosmithkline, LLC. | $152.34 | 2022-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $135.41 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $114.08 | 2023-2025 | Gemtesa |
| Lilly USA, LLC | $110.10 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $82.34 | 2023-2025 | Rexulti |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carie Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.